NuCana (NCNA) 6-K 19 May 20 2020 Q1 Unaudited Condensed Consolidated Statements of Operations Financial data

Cover Page

Cover Page	3 Months Ended
	Mar. 31, 2020
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Registrant Name	NUCANA PLC
Entity Central Index Key	0001709626
Current Fiscal Year End Date	--12-31

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations - GBP (£) £ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Profit or loss [abstract]
Research and development expenses	£ (5,938)	£ (4,350)
Administrative expenses	(1,609)	(1,346)
Net foreign exchange gains (losses)	2,127	(979)
Operating loss	(5,420)	(6,675)
Finance income	144	318
Loss before tax	(5,276)	(6,357)
Income tax credit	1,310	1,000
Loss for the period	£ (3,966)	£ (5,357)
Basic and diluted loss per share	£ (0.12)	£ (0.17)

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Statements of Comprehensive Loss - GBP (£) £ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of comprehensive income [abstract]
Loss for the period	£ (3,966)	£ (5,357)
Items that may be reclassified subsequently to profit or loss:
Exchange differences on translation of foreign operations	21	(5)
Other comprehensive income (expense) for the period	21	(5)
Total comprehensive loss for the period	(3,945)	(5,362)
Attributable to:
Equity holders of the Company	£ (3,945)	£ (5,362)

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Financial Position - GBP (£) £ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Non-current assets
Intangible assets	£ 4,246	£ 3,960
Property, plant and equipment	1,018	1,109
Deferred tax asset	44	46
Total non-current assets	5,308	5,115
Current assets
Prepayments, accrued income and other receivables	4,290	4,710
Current income tax receivable	9,797	8,481
Cash and cash equivalents	47,600	51,962
Total current assets	61,687	65,153
Total assets	66,995	70,268
Capital and reserves
Share capital and share premium	80,840	80,840
Other reserves	63,614	62,737
Accumulated deficit	(84,021)	(80,055)
Total equity attributable to equity holders of the Company	60,433	63,522
Non-current liabilities
Provisions	26	26
Lease liabilities	485	538
Total non-current liabilities	511	564
Current liabilities
Trade payables	2,456	2,412
Payroll taxes and social security	148	160
Lease liabilities	258	268
Accrued expenditure	3,189	3,342
Total current liabilities	6,051	6,182
Total liabilities	6,562	6,746
Total equity and liabilities	£ 66,995	£ 70,268

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Changes In Equity - GBP (£) £ in Thousands	Total	Share Capital [member]	Share Premium [member]	Own Share Reserve [member]	Share Option Reserve [member]	Foreign Currency Translation Reserve [member]	Capital Reserve [member]	Accumulated Deficit [member]
Beginning balance at Dec. 31, 2018	£ 81,594	£ 1,289	£ 79,426	£ (339)	£ 17,564	£ 1	£ 42,466	£ (58,813)
Loss for the period	(5,357)							(5,357)
Other comprehensive income (expense) for the period	(5)					(5)
Total comprehensive loss for the period	(5,362)					(5)		(5,357)
Share-based payments	384				384
Exercise of share options	34	1	33		(53)			53
Ending balance at Mar. 31, 2019	76,650	1,290	79,459	(339)	17,895	(4)	42,466	(64,117)
Beginning balance at Dec. 31, 2019	63,522	1,299	79,541	(339)	20,620	(10)	42,466	(80,055)
Loss for the period	(3,966)							(3,966)
Other comprehensive income (expense) for the period	21					21
Total comprehensive loss for the period	(3,945)					21		(3,966)
Share-based payments	856				856
Ending balance at Mar. 31, 2020	£ 60,433	£ 1,299	£ 79,541	£ (339)	£ 21,476	£ 11	£ 42,466	£ (84,021)

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Cash Flows - GBP (£) £ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities
Loss for the period	£ (3,966)	£ (5,357)
Adjustments for:
Income tax credit	(1,310)	(1,000)
Amortization and depreciation	217	161
Finance income	(144)	(318)
Share-based payments	856	384
Net foreign exchange (gains) losses	(2,164)	984
Cash flows from (used in) operations before changes in working capital	(6,511)	(5,146)
Movements in working capital:
Decrease (increase) in prepayments, accrued income and other receivables	423	(402)
Increase (decrease) in trade payables	44	(197)
Decrease in payroll taxes, social security and accrued expenditure	(165)	(347)
Movements in working capital	302	(946)
Cash used in operations	(6,209)	(6,092)
Net income tax received	0	0
Net cash used in operating activities	(6,209)	(6,092)
Cash flows from investing activities
Interest received	187	311
Payments for property, plant and equipment	(10)	(18)
Payments for intangible assets	(398)	(280)
Net cash (used in) from investing activities	(221)	13
Cash flows from financing activities
Payments for lease liabilities	(73)	(40)
Proceeds from issue of share capital	0	34
Net cash used in financing activities	(73)	(6)
Net decrease in cash and cash equivalents	(6,503)	(6,085)
Cash and cash equivalents at beginning of period	51,962	76,972
Effect of exchange rate changes on cash and cash equivalents	2,141	(979)
Cash and cash equivalents at end of period	£ 47,600	£ 69,908

General Information

General Information	3 Months Ended
	Mar. 31, 2020
Disclosure Of General Information About Financial Statements [Abstract]
General information	1. General information NuCana plc (“NuCana” or the “Company”) is a clinical-stage biopharmaceutical company developing a portfolio of new medicines to treat cancer. NuCana is harnessing the power of phosphoramidate chemistry to generate new medicines called ProTides. These compounds have the potential to improve cancer treatment by enhancing the efficacy and safety of several current standards of care. The Company has ordinary shares in the form of American Depositary Shares (“ADSs”) registered with the US Securities and Exchange Commission (the “SEC”) and has been listed on The Nasdaq Global Select The Company has two wholly owned subsidiaries, NuCana, Inc. and NuCana BioMed Trustee Company Limited (together referred to as the “Group”). The comparative figures for the year ended December 31, 2019 are not the Group’s statutory accounts for that financial year within the meaning of section 434 of the Companies Act 2006. Those accounts have not yet been reported on by the Company’s auditor or delivered to the Registrar of Companies. The Company filed its Annual Report on Form 20-F

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Disclosure Of Summary Of Significant Accounting Policies [Abstract]
Significant accounting policies	2. Significant accounting policies Basis of preparation The unaudited condensed consolidated financial statements (the “financial statements”) for the three months ended March 31, 2020 have been prepared in accordance with International Accounting Standard 34, “ Interim Financial Reporting” The financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company’s annual financial statements for the year ended December 31, 2019. In the opinion of management, these unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of the results of operations, financial position and cash flows. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results that can be expected for the Company’s fiscal year ending December 31, 2020. Going concern In common with many companies in the biopharmaceutical sector, the Company incurs significant expenditure in its early years as it researches and develops its potential products for market. The Company’s board of directors, having reviewed the operating budgets and development plans, considers that the Company has adequate resources to continue in operation for the foreseeable future. The board of directors is therefore satisfied that it is appropriate to adopt the going concern basis of accounting in preparing the financial statements. The Company believes that its cash and cash equivalents of £47.6 million at March 31, 2020 will be sufficient to fund its current operating plan for at least the next 12 months. Further, the directors have conducted a full assessment of the impact of COVID-19 COVID-19, As the Company continues to incur losses, the transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital. The Company currently has sufficient cash reserves to fund operations at least into the fourth quarter of 2021. There can be no assurances, however, that additional funding will be available on acceptable terms. Judgements and estimates The accounting estimates and judgements made by management in applying the Group’s accounting policies that have the most significant effect on the amounts included within these financial statements, were the same as those that applied to the annual financial statements for the year ended December 31, 2019.

Income Tax

Income Tax	3 Months Ended
	Mar. 31, 2020
Major Components Of Tax Expense Income [Abstract]
Income tax	3. Income tax For the Three Months Ended 2020 2019 (in thousands) £ £ Current tax: In respect of current period U.K. 1,315 1,007 In respect of current period U.S. — (1 ) 1,315 1,006 Deferred tax: In respect of current period U.S. (4 ) (6 ) In respect of prior period U.S. (1 ) — Income tax credit 1,310 1,000 The income tax credit recognized primarily represents the U.K. research and development tax credit. In the United Kingdom, the Company is able to surrender some of its losses for a cash rebate of up to 33.35% of expenditure related to eligible research and development projects. March 31, December 31, (in thousands) £ £ Current income tax receivable U.K. tax 9,793 8,477 U.S. tax 4 4 9,797 8,481 Deferred tax asset U.S. deferred tax asset 44 46

Basic and Diluted Loss Per Shar

Basic and Diluted Loss Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Basic and diluted loss per share	4. Basic and diluted loss per share For the Three Months Ended 2020 2019 (in thousands, except £ £ Loss for the period (3,966 ) (5,357 ) Basic and diluted weighted average number of shares 32,479 32,227 £ £ Basic and diluted loss per share (0.12 ) (0.17 ) Basic loss per share is calculated by dividing the loss for the period attributable to the equity holders of the Company by the weighted average number of shares outstanding during the period. The potential shares issued through equity settled transactions were considered to be anti-dilutive as they would have decreased the loss per share and were therefore excluded from the calculation of diluted loss per share.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2020
Disclosure Of Intangible Assets [Abstract]
Intangible assets	5. Intangible assets Intangible assets comprise patents with a carrying value of £4.0 million as of March 31, 2020 (as of December 31, 2019: £3.7 million) and computer software with a carrying value of £0.2 million as of March 31, 2020 (as of December 31, 2019: £0.3 million). During the three months ended March 31, 2020, the Company acquired intangible assets with a cost of £0.4 million in relation to patents. There were no disposals of intangible assets in the three months ended March 31, 2020.

Cash and Cash Equivalents

Cash and Cash Equivalents	3 Months Ended
	Mar. 31, 2020
Cash And Cash Equivalents [Abstract]
Cash and cash equivalents	6. Cash and cash equivalents March 31, December 31, (in thousands) £ £ Cash and cash equivalents 47,600 51,962 Cash and cash equivalents comprise cash at bank with maturities of three months or less and earn interest at fixed or variable rates based on the terms agreed for each account.

Share-based Payments

Share-based Payments	3 Months Ended
	Mar. 31, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
Share-based payments	7. Share-based payments The Company has three share-based payment plans for employees, directors and consultants. The share options granted will be settled in equity. No share options were granted during the three months ended March 31, 2020 (three months ended March 31, 2019: 120,750 share options granted). Options granted under these plans will vest if the option holder remains under respective contract of employment or contract of service for the agreed vesting period. For the three months ended March 31, 2020, the Company has recognized £0.9 million of share-based payment expense in the statement of operations (three months ended March 31, 2019: £0.4 million).

Share Capital and Share Premium

Share Capital and Share Premium	3 Months Ended
	Mar. 31, 2020
Disclosure Of Classes Of Share Capital [Abstract]
Share capital and share premium	8. Share capital and share premium March 31, December 31, (in thousands) £ £ Share capital 1,299 1,299 Share premium 79,541 79,541 80,840 80,840 March 31, December 31, Number (in thousands) Issued share capital comprises: Ordinary shares of £0.04 each 32,479 32,479 Number of Share Share (in thousands) Fully paid shares : £ £ Balance at December 31, 2019 and March 31, 2020 32,479 1,299 79,541

Contingent Liabilities

Contingent Liabilities	3 Months Ended
	Mar. 31, 2020
Disclosure Of Contingent Liabilities [Abstract]
Contingent liabilities	9. Contingent liabilities Under its U.K. share-based payment plan, the Company granted unapproved share options that have fully vested. If and when these share options are exercised, the Company will be liable for the Employer Class 1 National Insurance payable to HMRC in the United Kingdom. This contingent liability will be determined based on the market value of the shares on exercise less the exercise price paid by the option holders, at the prevailing rate of Employer National Insurance (currently 13.8%). Based on the closing price of the Company’s ADSs on the Nasdaq Global Select Market on March 31, 2020, the last trading day of the period to which these financial statements relate, and assuming full exercise of all outstanding and vested unapproved share options on that date, the Employer National Insurance contingent liability would have been £1.3 million (December 31, 2019: £1.3 million).

Events After the Reporting Peri

Events After the Reporting Period	3 Months Ended
	Mar. 31, 2020
Events After Reporting Period [Abstract]
Events After the Reporting Period	10. Events after the reporting period COVID-19 In December 2019, a novel strain of the coronavirus SARS-CoV-2, COVID-19, COVID-19 In response to the spread of COVID-19, on-site Also, in April 2020, the Company announced that in order ease the burden on clinical trial sites and enable healthcare professionals to focus their efforts on caring for patients with COVID-19, re-commenced NUC-3373 NUC-7738. COVID-19 COVID-19 At this time, there is no impact on the Company’s financial statements, including the judgements and estimates included in these financial statements. Proceeds from issue of share capital Since the end of the reporting period the Company has issued 139,489 ADSs, representing 139,489 ordinary shares, raising gross proceeds of £0.6 million.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Disclosure Of Summary Of Significant Accounting Policies [Abstract]
Basis of preparation	Basis of preparation The unaudited condensed consolidated financial statements (the “financial statements”) for the three months ended March 31, 2020 have been prepared in accordance with International Accounting Standard 34, “ Interim Financial Reporting” The financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company’s annual financial statements for the year ended December 31, 2019. In the opinion of management, these unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of the results of operations, financial position and cash flows. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results that can be expected for the Company’s fiscal year ending December 31, 2020.
Going concern	Going concern In common with many companies in the biopharmaceutical sector, the Company incurs significant expenditure in its early years as it researches and develops its potential products for market. The Company’s board of directors, having reviewed the operating budgets and development plans, considers that the Company has adequate resources to continue in operation for the foreseeable future. The board of directors is therefore satisfied that it is appropriate to adopt the going concern basis of accounting in preparing the financial statements. The Company believes that its cash and cash equivalents of £47.6 million at March 31, 2020 will be sufficient to fund its current operating plan for at least the next 12 months. Further, the directors have conducted a full assessment of the impact of COVID-19 COVID-19, As the Company continues to incur losses, the transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital. The Company currently has sufficient cash reserves to fund operations at least into the fourth quarter of 2021. There can be no assurances, however, that additional funding will be available on acceptable terms.
Judgements and estimates	Judgements and estimates The accounting estimates and judgements made by management in applying the Group’s accounting policies that have the most significant effect on the amounts included within these financial statements, were the same as those that applied to the annual financial statements for the year ended December 31, 2019.

Income Tax (Tables)

Income Tax (Tables)	3 Months Ended
	Mar. 31, 2020
Major Components Of Tax Expense Income [Abstract]
Schedule of Major Components of Income Tax	For the Three Months Ended 2020 2019 (in thousands) £ £ Current tax: In respect of current period U.K. 1,315 1,007 In respect of current period U.S. — (1 ) 1,315 1,006 Deferred tax: In respect of current period U.S. (4 ) (6 ) In respect of prior period U.S. (1 ) — Income tax credit 1,310 1,000 March 31, December 31, (in thousands) £ £ Current income tax receivable U.K. tax 9,793 8,477 U.S. tax 4 4 9,797 8,481 Deferred tax asset U.S. deferred tax asset 44 46

Basic and Diluted Loss Per Sh_2

Basic and Diluted Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Loss Per Share	For the Three Months Ended 2020 2019 (in thousands, except £ £ Loss for the period (3,966 ) (5,357 ) Basic and diluted weighted average number of shares 32,479 32,227 £ £ Basic and diluted loss per share (0.12 ) (0.17 )

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	3 Months Ended
	Mar. 31, 2020
Cash And Cash Equivalents [Abstract]
Schedule of Cash and Cash Equivalents	March 31, December 31, (in thousands) £ £ Cash and cash equivalents 47,600 51,962

Share Capital and Share Premi_2

Share Capital and Share Premium (Tables)	3 Months Ended
	Mar. 31, 2020
Disclosure Of Classes Of Share Capital [Abstract]
Summary of Share Capital and Share Premium	March 31, December 31, (in thousands) £ £ Share capital 1,299 1,299 Share premium 79,541 79,541 80,840 80,840 March 31, December 31, Number (in thousands) Issued share capital comprises: Ordinary shares of £0.04 each 32,479 32,479
Summary of Movement in the Share Capital	Number of Share Share (in thousands) Fully paid shares : £ £ Balance at December 31, 2019 and March 31, 2020 32,479 1,299 79,541

General Information - Additiona

General Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2020Subsidiary
Disclosure Of General Information About Financial Statements [Abstract]
Description of nature of entity's operations	clinical-stage biopharmaceutical company developing a portfolio of new medicines to treat cancer
Name of reporting entity	NuCana plc
Domicile of entity	United Kingdom
Country of incorporation	England and Wales
Number of subsidiaries	2
Name of subsidiary	NuCana, Inc. and NuCana BioMed Trustee Company Limited

Significant Accounting Polici_3

Significant Accounting Policies - Additional Information (Detail) - GBP (£) £ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Disclosure Of Summary Of Significant Accounting Policies [Abstract]
Cash and cash equivalents	£ 47,600	£ 51,962	£ 69,908	£ 76,972

Income Tax - Schedule of Major

Income Tax - Schedule of Major Components of Income Tax Credit (Detail) - GBP (£) £ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Current tax:
Total current tax	£ 1,315	£ 1,006
Deferred tax:
Income tax credit	1,310	1,000
U.K. [member]
Current tax:
In respect of current period	1,315	1,007
U.S. [member]
Current tax:
In respect of current period		(1)
Deferred tax:
In respect of current period	(4)	£ (6)
In respect of prior period	£ (1)

Income Tax - Additional Informa

Income Tax - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2020
U.K. [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Percentage of losses surrendered for R&D tax credit	33.35%

Income Tax - Schedule of Majo_2

Income Tax - Schedule of Major Components of Income Tax Assets (Detail) - GBP (£) £ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current income tax receivable
Current income tax receivable	£ 9,797	£ 8,481
Deferred tax asset
Deferred tax asset	44	46
U.K. [member]
Current income tax receivable
Current income tax receivable	9,793	8,477
U.S. [member]
Current income tax receivable
Current income tax receivable	4	4
Deferred tax asset
Deferred tax asset	£ 44	£ 46

Basic and Diluted Loss per Sh_3

Basic and Diluted Loss per Share - Schedule of Basic and Diluted Loss Per Share (Detail) - GBP (£) £ / shares in Units, £ in Thousands, shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Loss for the period	£ (3,966)	£ (5,357)
Basic and diluted weighted average number of shares	32,479	32,227
Basic and diluted loss per share	£ (0.12)	£ (0.17)

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - GBP (£) £ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about intangible assets [line items]
Intangible assets, carrying value	£ 4,246	£ 3,960
Patents [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets, carrying value	4,000	3,700
Intangible assets, acquired	400
Computer Software [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets, carrying value	£ 200	£ 300

Cash and Cash Equivalents - Sch

Cash and Cash Equivalents - Schedule of Detailed Information About Cash and Cash Equivalents (Detail) - GBP (£) £ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Cash And Cash Equivalents [Abstract]
Cash and cash equivalents	£ 47,600	£ 51,962	£ 69,908	£ 76,972

Share-based Payments - Addition

Share-based Payments - Additional Information (Details) £ in Millions	3 Months Ended
	Mar. 31, 2020GBP (£)shares	Mar. 31, 2019GBP (£)shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted in share-based payment arrangement | shares	0	120,750
Share-based payment expense | £	£ 0.9	£ 0.4

Share Capital and Share Premi_3

Share Capital and Share Premium - Summary of Share Capital and Share Premium (Detail) - GBP (£) £ in Thousands, shares in Thousands	Mar. 31, 2020	Dec. 31, 2019
Disclosure Of Classes Of Share Capital [Abstract]
Share capital	£ 1,299	£ 1,299
Share premium	79,541	79,541
Share capital and share premium	£ 80,840	£ 80,840
Ordinary shares of £0.04 each	32,479	32,479

Share Capital and Share Premi_4

Share Capital and Share Premium - Summary of Share Capital and Share Premium (Parenthetical) (Detail) - £ / shares	Mar. 31, 2020	Dec. 31, 2019
Ordinary shares [member]
Disclosure of classes of share capital [line items]
Par value per share	£ 0.04	£ 0.04

Share Capital and Share Premi_5

Share Capital and Share Premium - Summary of Movement in the Share Capital (Detail) - GBP (£) £ in Thousands, shares in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Disclosure of classes of share capital [line items]
Number of shares issued and fully paid	32,479	32,479
Fully paid shares	£ 60,433	£ 63,522	£ 76,650	£ 81,594
Share Capital [member]
Disclosure of classes of share capital [line items]
Fully paid shares	1,299	1,299	1,290	1,289
Share Premium [member]
Disclosure of classes of share capital [line items]
Fully paid shares	£ 79,541	£ 79,541	£ 79,459	£ 79,426

Contingent Liabilities - Additi

Contingent Liabilities - Additional Information (Detail) - GBP (£) £ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Disclosure Of Contingent Liabilities [Abstract]
Employer national insurance contingent liability	£ 1.3	£ 1.3
Prevailing rate of employer national insurance	13.80%

Events After the Reporting Pe_2

Events After the Reporting Period - Additional Information (Detail) - GBP (£) £ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Disclosure of non-adjusting events after reporting period [line items]
Issue of Ordinary shares	32,479,000	32,479,000
Non Adjusting Event After Reporting Date [Member]
Disclosure of non-adjusting events after reporting period [line items]
Issue of Ordinary shares	139,489
Proceeds from issue of share capital	£ 0.6